How has been the historical performance of Concord Biotech?

Answer:The historical performance of Concord Biotech shows a consistent growth trend across various financial metrics from March 2022 to March 2025.

Breakdown:
Concord Biotech's net sales have increased significantly from INR 712.93 crore in March 2022 to INR 1,200.09 crore in March 2025. The total operating income followed a similar upward trajectory, reaching INR 1,200.09 crore in March 2025, up from INR 712.93 crore in March 2022. Total expenditure, excluding depreciation, also rose from INR 439.66 crore in March 2022 to INR 693.76 crore in March 2025. Operating profit (PBDIT) has shown a robust increase, climbing from INR 296.69 crore in March 2022 to INR 550.78 crore in March 2025, while profit before tax rose from INR 241.16 crore to INR 495.87 crore in the same period. The profit after tax saw a substantial increase from INR 178.57 crore in March 2022 to INR 372.96 crore in March 2025. The earnings per share (EPS) also improved significantly, from INR 16.72 in March 2022 to INR 35.53 in March 2025. On the balance sheet, total assets grew from INR 1,312.79 crore in March 2022 to INR 2,034.25 crore in March 2025, while total liabilities increased from INR 1,312.79 crore to INR 2,034.25 crore. The cash flow from operating activities remained relatively stable, with a slight decrease from INR 265 crore in March 2024 to INR 244 crore in March 2025, and the company reported a net cash outflow of INR 14 crore in March 2025. Overall, Concord Biotech has demonstrated strong growth in sales, profits, and assets over the past few years.